Gastroesophageal reflux diseaseMANAGEMENT

GASTROINTESTINAL PRESENTATIONS · 12 SECTIONS

⚲

688 items

☷ Legend

01Approach to the Critical Patient/attcp57

Immediate risk stratification

›High-risk presentation screen

›Hemodynamic instability

›SBP < 90 mmHg

›Altered mental status

›Airway threat

›Stridor

›Inability to handle secretions

›Significant gastrointestinal bleeding

›Hematemesis

›Melena with syncope

›Esophageal perforation concern

›Severe chest pain after vomiting

›Subcutaneous emphysema

›Acute coronary syndrome not yet excluded

›Chest pressure with exertion

›Diaphoresis

›Immediate actions if unstable

›If shock, resuscitation bay and parallel workup

›IV access and monitoring

›ECG within 10 minutes for chest pain equivalent

›If active hematemesis, massive GI bleed pathway

›Blood product preparation

›Early gastroenterology consultation

›If perforation concern, broad-spectrum antibiotics and urgent CT chest with water-soluble contrast pathway

›Surgical consultation

›NPO status

›Chest pain safety overlay

›Noncardiac chest pain diagnosis only after appropriate cardiac evaluation

›Serial high-sensitivity troponin per local protocol

›Risk stratification tool per ED chest pain guideline

›ACEP chest pain guidance alignment

›Level A or Level B local pathway adherence for ECG and troponin in suspected ACS

›Avoid anchoring on reflux with ongoing ischemic concern

Key concepts

›Working diagnosis framework

›GERD symptom syndromes

›Typical reflux syndrome

›Heartburn

›Regurgitation

›Extraesophageal reflux syndrome

›Chronic cough

›Laryngitis symptoms

›Complication syndromes

›Erosive esophagitis

›Odynophagia

›GI bleeding signs

›Stricture

›Progressive solid food dysphagia

›Barrett esophagus risk phenotype

›Long-standing frequent symptoms

›Multiple risk factors

›Diagnostic strategy principle

›Empiric PPI trial appropriate for typical symptoms without alarm features

›Symptom response supports GERD but does not fully exclude alternative diagnoses

›Alarm features trigger early endoscopy rather than prolonged empiric therapy

›Dysphagia

›Unintentional weight loss

›GI bleeding or anemia

02History/hx79

Symptom characterization

›Reflux symptom profile

›Heartburn

›Substernal burning

›Postprandial pattern

›Regurgitation

›Sour or bitter fluid sensation

›Worse when bending or supine

›Chest pain

›Relationship to meals

›Exertional component

›Dyspepsia overlap

›Epigastric discomfort

›Early satiety

›Temporal pattern

›Duration

›Onset date

›Symptom frequency per week

›Diurnal variation

›Nocturnal symptoms

›Morning hoarseness

›Prior episodes

›Previous response to acid suppression

›Prior endoscopy results

Alarm features and complication clues

›Alarm features

›Dysphagia

›Solids then liquids progression

›Food impaction events

›Odynophagia

›Severe pain with swallowing

›Immunosuppression context

›GI bleeding

›Hematemesis

›Melena

›Unintentional weight loss

›Documented decline

›Reduced intake due to symptoms

›Persistent vomiting

›Dehydration signs

›Electrolyte concern

›Complication clues

›Stricture symptoms

›Progressive dysphagia

›Need for liquids to pass food

›Aspiration risk

›Choking episodes at night

›Recurrent pneumonias

›Barrett risk profile

›Long-standing symptoms

›Family history of Barrett or esophageal adenocarcinoma

Triggers, exposures, and risk factors

›Dietary triggers

›Large meals

›Postprandial worsening

›Late-night eating

›Common trigger foods

›High-fat meals

›Chocolate

›Caffeine and carbonated beverages

›Symptom correlation

›Quantity per day

›Lifestyle factors

›Tobacco use

›Current use

›Pack-year estimate

›Alcohol use

›Pattern and quantity

›Symptom association

›Obesity

›Recent weight gain

›Central adiposity

›Medication contributors

›Reduced LES tone potential

›Calcium channel blockers

›Nitrates

›Pill esophagitis risk

›Doxycycline

›Bisphosphonates

›Mucosal injury risk

›NSAIDs

›Aspirin

03Physical Exam/exam42

General and vital signs

›Physiologic status

›Vitals

›Tachycardia

›Fever

›Hydration

›Dry mucous membranes

›Orthostasis

›General appearance

›Toxic appearance

›Sepsis concern

›Perforation concern

›Pain behavior

›Severe distress

›Unable to tolerate oral intake

Focused examination

›Oropharynx and neck

›Oropharyngeal findings

›Erythema

›Thrush

›Neck exam

›Tenderness

›Crepitus

›Cardiopulmonary

›Cardiac exam

›New murmur

›Rhythm irregularity

›Lung exam

›Wheeze

›Rales suggesting aspiration

›Abdomen

›Epigastric tenderness

›Mild localized tenderness

›Guarding suggests alternative diagnosis

›Peritoneal signs

›Rebound tenderness

›Rigidity

›Signs of bleeding or anemia

›Conjunctival pallor

›Symptomatic anemia concern

›Need for CBC

›Rectal exam when indicated

›Melena

›Hematochezia

04Differential Diagnosis/ddx51

Life-threatening and must-not-miss

›Cardiac

›Acute coronary syndrome

›ICD-10 I20.0

›SNOMED CT acute coronary syndrome

›Aortic dissection

›ICD-10 I71.0

›Severe tearing pain phenotype

›Pericarditis

›ICD-10 I30.9

›Pleuritic pain and positional relief

›Pulmonary

›Pulmonary embolism

›ICD-10 I26.99

›Pleuritic pain and dyspnea

›Pneumothorax

›ICD-10 J93.9

›Unilateral decreased breath sounds

›Gastrointestinal emergencies

›Esophageal perforation

›ICD-10 K22.3

›Severe pain after vomiting

›Upper GI bleed

›ICD-10 K92.2

›Hematemesis or melena

Common mimics and overlaps

›Esophageal disorders

›Eosinophilic esophagitis

›Food impaction history

›Atopy history

›Achalasia

›Progressive dysphagia

›Regurgitation of undigested food

›Esophageal spasm

›Intermittent chest pain

›Dysphagia episodes

›Gastric and duodenal disorders

›Functional dyspepsia

›Postprandial fullness

›Epigastric pain syndrome

›Peptic ulcer disease

›NSAID exposure

›Nocturnal pain pattern

›Hepatobiliary and pancreatic

›Biliary colic

›RUQ pain after fatty meals

›Radiation to back or shoulder

›Acute cholecystitis

›Fever and RUQ tenderness

›Positive Murphy sign

›Pancreatitis

›Epigastric pain to back

›Lipase elevation

05Laboratory Tests/lt38

Basic tests when indicated

›Targeted labs by phenotype

›Complete blood count for bleeding or anemia concern

›Low hemoglobin suggests GI blood loss

›Leukocytosis suggests infection or complication

›Electrolytes and renal function for vomiting or dehydration

›Hypokalemia with prolonged emesis

›AKI risk with poor intake

›Liver enzymes and bilirubin for RUQ pain or biliary concern

›Cholestatic pattern suggests biliary obstruction

›Marked transaminitis suggests alternative diagnosis

›Lipase for pancreatitis phenotype

›Elevation supports pancreatitis

›Normal value does not exclude early disease

›Pregnancy testing

›Beta hCG for reproductive potential

›Hyperemesis differential

›Medication selection implications

Cardiac and pulmonary rule-out labs

›Chest pain safety labs

›High-sensitivity troponin when ACS in differential

›Serial testing per protocol

›Normal early value may require repeat testing

›D-dimer when PE workup appropriate

›Use only with low or intermediate pretest probability

›Avoid in high pretest probability as rule-out strategy

H pylori and anemia evaluation

›H pylori testing context

›Dyspepsia predominant phenotype

›Stool antigen testing option

›Urea breath testing option

›Testing caveats with acid suppression

›PPI can reduce test sensitivity

›Recent antibiotics can reduce test sensitivity

›Iron studies when chronic blood loss suspected

›Ferritin

›Low ferritin supports iron deficiency

›Inflammation can elevate ferritin

›Transferrin saturation

›Low saturation supports iron deficiency

›Consider chronic disease anemia alternative

06Diagnostic Tests/dt97

Scoring Systems

›Symptom-based tools

›GERD-Q questionnaire

›Higher scores increase probability of GERD

›Best use in primary care phenotype

›Alarm feature checklist

›Any alarm feature prompts early endoscopy pathway

›Persistent dysphagia prompts urgent evaluation

›ED risk tools for chest pain overlap

›HEART score for chest pain phenotype

›Supports ACS risk stratification

›Not a GERD diagnostic tool

›ACEP aligned chest pain pathways

›Level A or Level B recommendation adherence per institution

›Shared decision-making documentation for low-risk discharge

MRI

›Limited role in uncomplicated GERD

›Routine MRI not indicated for typical symptoms

›Low diagnostic yield

›Cost and access limitations

›Selected indications

›Neurologic dysphagia workup alternative diagnosis

›Mediastinal process evaluation when CT contraindicated

›Interpretation limitations

›Reflux events not reliably captured

›Dynamic physiologic condition

›Better assessed by pH impedance testing

›Indications for CT imaging

›Alternative diagnosis concern

›Aortic pathology phenotype

›Pulmonary embolism phenotype

›Complication concern

›Perforation concern

›Abscess concern

›Severe abdominal pain with systemic signs

›Peritonitis signs

›Sepsis concern

›CT findings that support reflux complications

›Esophageal wall thickening

›Esophagitis possibility

›Nonspecific finding

›Hiatal hernia

›Predisposition to reflux

›Size correlates with symptom severity imperfectly

›Pneumomediastinum

›Perforation concern

›Urgent surgical evaluation trigger

›Decision rule and guideline integration

›Avoid CT for uncomplicated typical GERD symptoms

›Radiation risk without benefit

›Prefer empiric therapy or endoscopy based on features

Ultrasound

›Abdominal ultrasound for biliary mimic

›RUQ pain phenotype

›Gallstones

›Gallbladder wall thickening

›Murphy sign correlation

›Positive sign supports cholecystitis

›Negative sign does not fully exclude

›Point-of-care ultrasound adjuncts

›Cardiac POCUS for chest pain alternative

›Pericardial effusion

›Regional wall motion abnormality context

›Lung POCUS for respiratory symptoms

›Pneumothorax signs

›Consolidation suggesting aspiration

Endoscopy

›Upper endoscopy indications

›Alarm features

›Dysphagia

›GI bleeding

›Refractory symptoms despite optimized PPI

›Persistent symptoms after adequate trial

›Uncertain diagnosis

›Barrett screening consideration in higher-risk phenotype

›Multiple risk factors present

›Long-standing frequent symptoms

›Endoscopic findings

›Erosive esophagitis

›LA classification framework use

›Higher grades correlate with GERD

›Barrett esophagus

›Columnar mucosa in distal esophagus

›Biopsy required for intestinal metaplasia confirmation

›Stricture

›Luminal narrowing

›Dilation consideration

pH monitoring and manometry

›Ambulatory pH or pH impedance testing

›Diagnostic uncertainty with normal endoscopy

›Objective reflux confirmation

›Symptom association analysis

›Preoperative evaluation for anti-reflux surgery consideration

›Objective reflux confirmation

›Predicts surgical benefit

›Esophageal manometry

›Dysphagia evaluation for motility disorders

›Achalasia pattern

›Hypercontractile disorders

›Preoperative planning

›Major motility disorder exclusion

›Wrap selection guidance

07Disposition/dispo34

ED and inpatient decision points

›Admission criteria

›Inability to tolerate oral intake

›Dehydration requiring IV fluids

›Persistent vomiting

›GI bleeding

›Hemodynamic changes

›Significant anemia

›Suspected perforation

›CT or clinical evidence

›Need for surgery or ICU monitoring

›High-risk chest pain not ruled out

›Abnormal ECG

›Troponin elevation

›Observation unit criteria

›Chest pain low to intermediate risk requiring serial testing

›Serial troponin completion

›Stress testing or CT coronary angiography per protocol

›Refractory symptoms requiring short-term symptom control

›IV antiemetics or acid suppression

›Oral challenge prior to discharge

Discharge criteria and follow-up

›Safe discharge phenotype

›Typical symptoms without alarm features

›Stable vitals

›Tolerating oral intake

›Symptoms responsive to initial therapy

›Relief with antacid or PPI

›No concerning exam findings

›Follow-up planning

›Primary care or gastroenterology referral

›Persistent symptoms after initial course

›Recurrent symptoms needing long-term plan

›Endoscopy referral triggers

›Any alarm feature

›Refractory symptoms despite optimized regimen

08Treatment/t133

Nonpharmacologic management

›Lifestyle and behavioral therapy

›Weight reduction when overweight or obese

›Symptom improvement expectation

›Lower intra-abdominal pressure rationale

›Meal timing and portion adjustments

›Avoid large meals

›Avoid eating within 2 to 3 hours of bedtime

›Head-of-bed elevation for nocturnal symptoms

›Bed risers or wedge pillow

›Avoid stacked pillows only

›Trigger identification and reduction

›High-fat meals

›Caffeine if clearly linked

›Tobacco cessation

›LES tone improvement rationale

›Barrett and cancer risk reduction rationale

Acid suppression and mucosal protection

›Medication strategy selection

›Typical symptoms without alarm features

›Initial PPI trial

›Duration 8 weeks

›Dosing once daily before breakfast

›Step-down after response

›Lowest effective dose

›On-demand use option for nonerosive disease

›Mild intermittent symptoms

›Antacids or alginate-based therapy

›Rapid symptom relief role

›Breakthrough symptom use

›Proton pump inhibitors

›Omeprazole PO 20 mg daily

›If partial response, increase to 20 mg twice daily

›Second dose before dinner

›Reassess after 4 to 8 weeks

›Maximum typical outpatient dosing 40 mg twice daily

›Use for refractory or erosive disease phenotype

›De-escalate when controlled

›Pantoprazole PO 40 mg daily

›If partial response, increase to 40 mg twice daily

›Timing 30 to 60 minutes before meals

›Check adherence and timing before escalating

›Maximum typical outpatient dosing 40 mg twice daily

›Shortest effective duration principle

›Long-term risk counseling

›Esomeprazole PO 20 mg daily

›If partial response, increase to 20 mg twice daily

›Consider CYP2C19 variability context

›Avoid duplication with other PPIs

›Maximum typical outpatient dosing 40 mg twice daily

›Consider specialist input at high dose

›Objective testing for refractory symptoms

›H2 receptor antagonists

›Famotidine PO 10 mg to 20 mg as needed

›Breakthrough symptoms on PPI

›Bedtime dose for nocturnal acid breakthrough

›Tolerance with nightly use

›Renal impairment dose adjustment

›Lower dose with reduced eGFR

›Monitor confusion risk in older adults

›Famotidine PO 20 mg twice daily

›Mild to moderate symptoms alternative

›Less effective than PPI for erosive esophagitis

›Consider step-up to PPI if persistent

›Maximum typical dose 40 mg twice daily

›Avoid prolonged high-dose without reassessment

›Consider endoscopy if persistent symptoms

›Antacids and alginates

›Calcium carbonate PO 500 mg to 1000 mg as needed

›Rapid relief role

›Short duration effect

›Avoid overuse with hypercalcemia risk

›Constipation risk

›Hydration advice

›Alternative antacid selection

›Alginate-based therapy after meals and at bedtime

›Postprandial reflux barrier mechanism

›Useful for regurgitation phenotype

›Add-on to PPI for symptoms

›Sodium load consideration

›Heart failure patients caution

›Hypertension patients caution

›Sucralfate

›Sucralfate PO 1 g four times daily

›Pregnancy symptom option

›Minimal systemic absorption

›Constipation risk

›Drug interaction spacing

›Separate from other meds by 2 hours

›Reduced absorption risk

Refractory symptoms and optimization

›Optimization checklist before labeling refractory GERD

›Adherence verification

›Daily dosing

›Missed doses frequency

›Timing correction

›30 to 60 minutes before breakfast

›Before dinner for twice daily regimens

›Phenotype reassessment

›Functional heartburn possibility

›Reflux hypersensitivity possibility

›Next steps when persistent symptoms

›Objective testing consideration

›Endoscopy for alarm features or long-standing symptoms

›pH impedance testing for uncertain diagnosis

›Alternative diagnoses evaluation

›Eosinophilic esophagitis

›Achalasia

›Adjunctive therapies by phenotype

›Bedtime H2RA for nocturnal symptoms

›Alginate therapy for regurgitation

Procedural and surgical options

›Anti-reflux procedures

›Laparoscopic fundoplication

›Indications

›Objective GERD with persistent symptoms

›Preference to avoid long-term medication

›Preoperative workup

›pH testing confirmation when endoscopy nonerosive

›Manometry to exclude major motility disorder

›Evidence statement

›Class I recommendation for surgery in selected patients with objective reflux and appropriate workup

›Shared decision-making on dysphagia and gas-bloat risks

›Magnetic sphincter augmentation

›Indications

›Objective GERD with normal motility

›Regurgitation predominant phenotype

›Contraindications

›Severe esophagitis

›Large hiatal hernia without repair plan

›Endoscopic therapies

›Selected patient use

›Mild to moderate disease phenotype

›Not for high-grade esophagitis

›Counseling on durability limits

›Variable long-term outcomes

›Continue surveillance for complications

09Special Populations/sp50

Pregnancy

›Pregnancy-focused approach

›Nonpharmacologic first

›Smaller meals

›Head-of-bed elevation

›Medication escalation sequence

›Antacids

›Calcium carbonate preferred option

›Avoid sodium bicarbonate routine use

›Sucralfate

›Minimal systemic absorption

›Constipation counseling

›H2RA

›Famotidine commonly used

›Use lowest effective dose

›PPI for persistent symptoms

›Use when benefits outweigh risks

›Consider obstetric input for severe disease

›Hyperemesis overlap caution

›Persistent vomiting evaluation

›Dehydration and electrolyte monitoring

Geriatric

›Older adult considerations

›Atypical presentation

›Less prominent heartburn

›More dysphagia or cough

›PPI risk mitigation

›Use lowest effective dose

›Periodic deprescribing attempt

›Adverse effect awareness

›C difficile infection association

›Fracture risk association

›Polypharmacy and interactions

›Antiplatelet therapy context

›Mineral supplementation timing

Pediatrics

›Pediatric reflux versus GERD distinction

›Physiologic reflux in infants

›Frequent regurgitation with normal growth

›Reassurance and feeding guidance

›GERD indicators

›Poor weight gain

›Feeding refusal

›Pediatric management approach

›Nonpharmacologic first-line in infants

›Avoid overfeeding

›Thickened feeds when appropriate

›Medication use caution

›Acid suppression only when clear GERD phenotype

›Short trial with reassessment

›Specialist referral triggers

›GI bleeding

›Persistent dysphagia or food impaction

10Background/b44

Epidemiology

›Population burden

›Common condition in adults

›High prevalence in primary care and ED chest pain mimic

›Frequent chronic or relapsing course

›Risk factors

›Obesity association

›Hiatal hernia association

›Complication risk

›Barrett esophagus risk increases with long-standing frequent symptoms

›Esophageal adenocarcinoma risk increases with Barrett presence

Pathophysiology

›Core mechanisms

›Lower esophageal sphincter dysfunction

›Transient LES relaxations

›Reduced basal LES tone

›Hiatal hernia contribution

›Disruption of gastroesophageal junction barrier

›Increased reflux episodes when supine

›Impaired esophageal clearance

›Reduced peristalsis

›Reduced salivary buffering

›Gastric factors

›Delayed gastric emptying

›Increased gastric volume after large meals

Therapeutic Considerations

›PPI pharmacology pearls

›Best effect with pre-meal dosing

›Proton pump activation with meals

›Suboptimal effect with bedtime-only dosing

›Time to maximal benefit

›Several days for full acid suppression

›Avoid premature escalation before optimization

›Deprescribing principle

›Step-down after symptom control

›On-demand use for nonerosive disease when appropriate

›Long-term acid suppression risks

›Association signals

›Enteric infection risk

›Hypomagnesemia risk

›Risk reduction strategies

›Lowest effective dose

›Periodic reassessment of ongoing indication

›Extraesophageal symptom caution

›Chronic cough and laryngeal symptoms have multifactorial causes

›Avoid assuming GERD without supportive features

›Consider objective testing before prolonged high-dose PPI

11Patient Discharge Instructions/pdi40

copy discharge instructions

›Diagnosis and expectations

›Symptoms consistent with acid reflux

›Often improves with lifestyle changes and acid-lowering medicine

›May take several days for best effect with daily PPI

›Medication plan

›Take PPI 30 to 60 minutes before breakfast

›Do not stop suddenly if symptoms severe without plan

›Home care

›Meal and sleep changes

›Avoid large meals

›Avoid eating within 2 to 3 hours of bedtime

›Bed positioning

›Raise head of bed

›Sleep on wedge if needed

›Trigger tracking

›Note foods that worsen symptoms

›Reduce those triggers if consistent

›Return to ED now if any occur

›Chest pain with exertion

›Pressure or squeezing quality

›Sweating or shortness of breath

›Trouble swallowing

›Food stuck

›Drooling or inability to swallow liquids

›Vomiting blood or black stools

›Red or coffee-ground vomit

›Black tarry stool

›Severe or worsening belly pain

›Pain with fever

›Rigid abdomen

›Unintentional weight loss

›Ongoing loss over weeks

›Progressive weakness

›Follow-up

›Primary care in 1 to 2 weeks if not improving

›Medication adjustment

›Referral discussion

›Gastroenterology referral triggers

›Any trouble swallowing

›Symptoms not improving after an adequate trial

12References/r23

Clinical guidelines and society statements

›Guideline sources

›American College of Gastroenterology guideline for GERD management

›Empiric PPI trial for typical symptoms without alarm features

›Endoscopy for alarm features and selected refractory cases

›American Gastroenterological Association clinical practice updates on PPI use

›Use lowest effective dose

›Deprescribing when no ongoing indication

›NICE guidance for dyspepsia and GERD

›Stepwise therapy and review

›Referral for alarm features

›ACEP clinical policies relevant to chest pain overlap

›Level A or Level B recommendations for ECG and troponin in suspected ACS pathways

›Discharge criteria for low-risk chest pain per institutional protocol

Evidence-based sources and decision support

›Foundational evidence

›PPI superiority over H2RA for healing erosive esophagitis

›Higher healing rates in trials and meta-analyses

›Symptom control benefit in frequent heartburn

›Ambulatory reflux monitoring utility

›Objective confirmation for refractory symptoms

›Symptom association analysis value

›Preoperative testing standards for anti-reflux surgery

›pH monitoring when diagnosis uncertain

›Manometry to exclude major motility disorder

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.